-

$undefined

N/A

(N/A)

Adaptimmune Therapeutics NASDAQ:ADAP Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Location: 60 Jubilee Avenue, Oxfordshire, OX14 4RX, United Kingdom | Website: www.adaptimmune.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

739.7M

Cash

214.8M

Avg Qtr Burn

-11.1M

Short % of Float

0.52%

Insider Ownership

0.38%

Institutional Own.

60.27%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TECELRA (afamitresgene autoleucel) Details Cancer, Synovialsarcoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lete-cel (NY-ESO) Details Myxoid/Round cell liposarcoma, Sarcoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uzatresgene autoleucel /uza-cel (ADP-A2M4CD8 )(MAGE A4) +/- nivolumab Details Cancer, Ovarian cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gavo-cel (TC-210) (Mesothelin) + nivolumab Details Solid tumor/s, Ovarian cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Uzatresgene autoleucel (uza-cel)(ADP-A2M4CD8) (MAGE A4) +/- nivolumab Details Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TC-510 Details Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADP-A2AFP Details Hepatocellular carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.